Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 6/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.48 |
| ▸ | CNR1 | P21554 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | PRNP | P04156 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | EDNRA | P25101 | 1/20 | 0.45 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453340 | 0.85 | MAPK1 (0.55) | LMNAMAPK1CNR2L3MBTL1CNR1 | |
| SCHEMBL9495317 | 0.77 | LMNA (0.82) | LMNAMAPK1CNR2L3MBTL1CNR1 | |
| SCHEMBL29448323 | 0.77 | PRNP (0.53) | LMNAMAPK1CNR2L3MBTL1CNR1 | |
| SCHEMBL2206020 | 0.77 | MCL1 (0.49) | LMNAMAPK1CNR2L3MBTL1CNR1 | |
| SCHEMBL1398747 | 0.77 | PRNP (0.53) | LMNAMAPK1CNR2L3MBTL1CNR1 | |
| SCHEMBL6231818 | 0.76 | ACLY (0.45) | LMNAMAPK1CNR2L3MBTL1CNR1 | |
| SCHEMBL9272529 | 0.76 | PTPN2 (0.43) | LMNAMAPK1CNR2L3MBTL1CNR1 | |
| SCHEMBL6234185 | 0.74 | MCL1 (0.55) | LMNAMAPK1CNR2L3MBTL1CNR1 | |
| SCHEMBL29664668 | 0.74 | MCL1 (0.65) | LMNAMAPK1ATMPRNPRXFP1 | |
| SCHEMBL941112 | 0.74 | MCL1 (0.65) | LMNAMAPK1ATMPRNPRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1334095-B1 | PROCESS FOR THE PREPARATION OF PGD2 ANTAGONIST | SHIONOGI & CO (JP) | 2005-01-19 | — | — | EP | disclosed |
| EP-1334095-A4 | PROCESS FOR THE PREPARATION OF PGD2 ANTAGONIST | SHIONOGI & CO (JP) | 2004-03-17 | — | — | EP | disclosed |
| US-6693203-B2 | REACTING NOPINONE ENOLATE WITH ALKYL 7-HALO-5-HEPTYNOATE, REACTING PRODUCT WITH HYDROXYLAMINE, TREATING WITH TITANIUM TRICHLORIDE AND BORANE REAGENT, HYDROGENATING, REACTING WITH 5-HYDROXY-4-BENZOTHIOPHENECARBOXYLIC ACID, HYDROLYZING | SHIONOGI & CO., LTD (JP) | 2004-02-17 | — | — | US | disclosed |
| US-20030199702-A1 | Process for the preparation of pgd2 antagonist | LARSEN ROBERT (US) | 2003-10-23 | — | — | US | disclosed |
| EP-1334095-A1 | PROCESS FOR THE PREPARATION OF PGD2 ANTAGONIST | SHIONOGI & CO., LTD. (JP) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002032892-A1 | PROCESS FOR THE PREPARATION OF PGD2 ANTAGONIST | SHIONOGI & CO., LTD (JP) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199702-A1 | Process for the preparation of pgd2 antagonist | PTGDR, PTGDR2, PTGER2 | LMNA 2300/4885MAPK1 3271/4885CNR2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.